This company applies advanced AI and bioengineering techniques, similar to those used in pharmaceutical development, to discover novel molecules for beauty and wellness applications. Their scalable platform screens vast molecular libraries to identify new ingredients that target specific skin, hair, and wellness challenges. The resulting proprietary molecules offer superior clinical efficacy compared to existing market formulations.
Funding
Funding not disclosed
Founders
Product
Problem
The beauty and wellness industry has seen limited innovation in ingredient discovery, relying on retesting and reformulating existing ingredients rather than developing novel molecules. This stagnation results in consumers experiencing underwhelming results from available products.
Solution
Revela, now Oddity Labs, employs an AI-driven molecular discovery platform to identify and develop novel molecules for consumer health products. By leveraging machine learning and bioengineering techniques typically used in pharmaceutical research, Revela aims to create ingredients with superior clinical efficacy compared to existing market offerings. Their technology screens billions of molecules to target challenges in hair, skin, and total body wellness, reinventing product performance by discovering molecules that directly address consumer needs. The company's multi-layered technology platform bridges molecule discovery and product development through advanced biological models, robotic phenotypic screening, and in silico molecular screening.
Target Audience
Revela's primary customers are consumers seeking innovative and effective beauty and wellness products, as well as the broader consumer goods industry looking to incorporate novel, scientifically-backed ingredients into their product lines.
Features
- AI-driven molecular discovery platform for identifying novel ingredients
- Advanced biological models, assay development, and synthetic biology for molecule development
- Robotic phenotypic screening, omic sequencing, and medicinal chemistry for data generation
- In silico molecular screening, deep learning, and computational biology for AI molecule screening and optimization
- In vitro efficacy validation, safety & toxicity screening, and ex vivo & clinical testing for lead validation
- Analytical chemistry and formulation for product development
- Over 200 molecules patent pending
- Screening capacity of over 25,000 molecules per second